The cancellation of a compulsory licence to Hyderabad-based Natco Pharma Ltd to make and sell the generic equivalent of cancer drug Nexavar will not impact public interest as there is another company selling it at a lower price, the Bayer Corporation said here Monday. Bayer Corp, the north American subsidiary of German company Bayer AG, has challenged the March order of the Controller General of Patents, Designs and Trade Marks of compulsorily licensing Natco Pharma to market the generic version of Nexavar (sorafenib tosylate) at the Intellectual Property Appellate Board (IPAB).
